Using bi-transgenic TRAMP mouse models of prostate cancer, soluble MICB was shown to promote carcinoma progression by depleting peripheral NK cells, whereas membrane-restricted MICB supported long-term tumor-free survival through sustained NKG2D-mediated anti-tumor immunity [40]. Here, KLRK1 is linked to carcinoma.